Revvity, Inc. (RVTY)
| Market Cap | 14.57B |
| Revenue (ttm) | 3.36B |
| Net Income (ttm) | 961.69M |
| Shares Out | 125.44M |
| EPS (ttm) | 7.60 |
| PE Ratio | 15.22 |
| Forward PE | n/a |
| Dividend | $0.28 (0.24%) |
| Ex-Dividend Date | Jul 20, 2023 |
| Volume | 219,614 |
| Open | 116.11 |
| Previous Close | 115.67 |
| Day's Range | 114.08 - 116.12 |
| 52-Week Range | 113.17 - 170.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2023 |
About RVTY
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical techno... [Read more]
Financial Performance
In 2023, Revvity's revenue was $3.31 billion, a decrease of -13.48% compared to the previous year's $3.83 billion. Earnings were $569.18 million, a decrease of -39.65%.
Financial StatementsNews
Revvity's EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced today that its EUROIMMUN business has launched the UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) syst...
Revvity to Present at Goldman Sachs Global Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 44th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 13, 2023 at 8:40 a.m. PT at the Waldorf Astoria ...
PerkinElmer Completes Transformation to Become Revvity
On Tuesday, May 16, the name PerkinElmer and its PKI symbol disappeared from the stock market. In its place is a piece of the old company, branded as Revvity Inc. ( RVTY , Financial).
Revvity Announces Financial Results for the First Quarter of 2023
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compar...
PerkinElmer Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of PerkinElmer, Inc. (NYSE: PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on Aug...
PerkinElmer to Hold Earnings Call on Thursday, May 11, 2023
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc. (NYSE: PKI), today announced that it will release its first quarter 2023 financial results prior to market open on Thursday, May 11, 2023. The Company...
Dirk Bontridder Appointed as CEO of New PerkinElmer Business Acquired by New Mountain Capital
NEW YORK--(BUSINESS WIRE)--The new PerkinElmer business acquired by New Mountain Capital announced today the appointment of Dirk Bontridder as Chief Executive Officer effective March 13, 2023. The new...
PerkinElmer Completes Divestiture of its Applied, Food and Enterprise Services Businesses
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc. (NYSE: PKI), today announced that it has successfully completed the previously announced divestiture of its Applied, Food and Enterprise Services busi...
PerkinElmer to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the virtual KeyBanc Capi...
PerkinElmer Launches EnVison Nexus Multimode Plate Reader to Drive Improved Research and Discovery Workflows
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer launches EnVision® Nexus™ system, its fastest, most sensitive multimode reader yet, for HTS to accelerate drug discovery efforts.
PerkinElmer to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Cowen 43rd Annual He...
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2022
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year end...
Adolore Biotherapeutics Strengthens Management Team and Board of Directors with the Appointments of Roelof Rongen, MSE, MBA and Mark C. Rogers, MD, MBA
Mr. Rongen appointed as CEO and member of the Board bringing 30 years of executive leadership experience and expertise across a number of therapeutic areas Bolstered expertise on Board of Directors wi...
Prahlad Singh Appointed to Board of Directors of Amphenol Corporation
WALLINGFORD, Conn.--(BUSINESS WIRE)--Amphenol Corporation (NYSE: APH) today announced that Prahlad Singh, PhD has been appointed to Amphenol's board of directors. With his appointment, the size of t...
PerkinElmer To Hold Earnings Call on Tuesday, February 14, 2023; Updates Fourth Quarter Outlook
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it will release its fourth quarter and full year 2...
PerkinElmer to Present at J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual J.P. Morgan...
PerkinElmer Helps Accelerate Gene Therapy Research with Industry-First Ready-to-Use Viral Vector Assays
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., (NYSE:PKI), a global leader committed to innovating for a healthier world, today launched ready-to-use Adeno-associated Virus Vectors (AAV) Detect...
PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the U.S. Food and Drug Administration (FDA) has aut...
PerkinElmer to Present at 2022 Stifel Healthcare Conference
WALTHAM, Mass.
PerkinElmer Announces Financial Results for the Third Quarter of 2022
WALTHAM, Mass.
PerkinElmer Bolsters Sustainability Commitments and Builds Off Recent Progress in New ESG Report
WALTHAM, Mass.
EPIC SCIENCES EXPANDS EXECUTIVE TEAM AND WELCOMES NEW CHIEF FINANCIAL OFFICER IN PREPARATION FOR RAPID GROWTH
Bill Kullback Brings Proven Track Record of Scaling Companies for Successful Outcomes SAN DIEGO , Nov. 1, 2022 /PRNewswire/ -- Epic Sciences, Inc. ("Epic" or "Epic Sciences"), a privately held diagnos...
PerkinElmer to Hold Earnings Call on Tuesday, November 8, 2022; Updates Third Quarter Outlook
WALTHAM, Mass.
PerkinElmer Donation Helps Significantly Expand Capacity for Sickle Cell Disease Screening in Ghana
WALTHAM, Mass.
PerkinElmer Unveils Industry-first Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the Cellaca® PLX Image Cytometry System, a first-of-its-k...